November 1, 2017: A very busy year! We’ve been working through the more than 100 founders produced over the past 12 months. We have multiple new expressing transgenic lines and more to come. Check out our mouse production page to see new information on smooth muscle lines acta2-optoα1AR-IRES-lacZ and acta2-GCaMP8.1-mVermilion; venous system lines HCN4-CatCh-IRES-lacZ, Cdh5-Optoα1AR-IRES-lacZ, Cdh5-optoβ2AR-IRES-lacZ and Cdh5-CatCh-IRES-lacZ; and lung epithelial line SP-C-GCaMP8.
Here’s a quick look at some of the new lines:
Interested in a line not listed? Questions on how to obtain our mice? Contact us!
September 24, 2016: NEW LINES AVAILABLE! New lines expressed in cardiac, venous, endothelial and smooth muscle systems are now available. Rhodopsin based effectors expressed under control of acta2, HCN4 and αMHC promoters, as well as new GCaMP8 lines expressed under control of αMHC and cdh5 promoters are our latest additions. Visit our mouse production page for more information on these and other upcoming lines.
October 16, 2015: New lines available! We have two new lines ready for distribution. acta2-RCaMP1.07 expresses a red calcium indicator in smooth muscle cells. HCN4-GCaMP8 expresses a green calcium indicator in the SA node and AV node. Additionally, other mice previously created in the Kotlikoff laboratory have been added to CHROMus and can be obtained through Jackson Labs. Visit our mouse production page for more information on these and other upcoming lines.
January 8, 2015: A new year and great progress is being made. We have founders from 6 transgenic constructs and are now analyzing their expression patterns. We’ve added a lacZ tag to the rhodopsin based constructs to allow for easy detection.
November 6, 2014: Check out our review article in frontiers in PHYSIOLOGY “Optogenetic sensors and effectors: CHROMus—the Cornell Heart Lung Blood Institute Resource for Optogenetic Mouse Signaling“
September 9, 2014: Article about CHROMusTM published at http://www.vet.cornell.edu/news/optogenetics.cfm
August 1, 2014: Dr. Kotlikoff awarded NIH grant to develop transgenic mice useful to the NHLBI community, work begins on the transgenes!